RT Journal Article
SR Electronic
T1 Deciphering Distinct Genetic Risk Factors for FTLD-TDP Pathological Subtypes via Whole-Genome Sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.24.24309088
DO 10.1101/2024.06.24.24309088
A1 Pottier, Cyril
A1 Küçükali, Fahri
A1 Baker, Matt
A1 Batzler, Anthony
A1 Jenkins, Gregory D.
A1 van Blitterswijk, Marka
A1 Vicente, Cristina T.
A1 De Coster, Wouter
A1 Wynants, Sarah
A1 Van de Walle, Pieter
A1 Ross, Owen A.
A1 Murray, Melissa E.
A1 Faura, Júlia
A1 Haggarty, Stephen J.
A1 van Rooij, Jeroen GJ.
A1 Mol, Merel O.
A1 Hsiung, Ging-Yuek R.
A1 Graff, Caroline
A1 Öijerstedt, Linn
A1 Neumann, Manuela
A1 Asmann, Yan
A1 McDonnell, Shannon K.
A1 Baheti, Saurabh
A1 Josephs, Keith A.
A1 Whitwell, Jennifer L.
A1 Bieniek, Kevin F.
A1 Forsberg, Leah
A1 Heuer, Hilary
A1 Lago, Argentina Lario
A1 Geier, Ethan G.
A1 Yokoyama, Jennifer S.
A1 Oddi, Alexis P.
A1 Flanagan, Margaret
A1 Mao, Qinwen
A1 Hodges, John R.
A1 Kwok, John B.
A1 Domoto-Reilly, Kimiko
A1 Synofzik, Matthis
A1 Wilke, Carlo
A1 Onyike, Chiadi
A1 Dickerson, Bradford C.
A1 Evers, Bret M.
A1 Dugger, Brittany N.
A1 Munoz, David G.
A1 Keith, Julia
A1 Zinman, Lorne
A1 Rogaeva, Ekaterina
A1 Suh, EunRan
A1 Gefen, Tamar
A1 Geula, Changiz
A1 Weintraub, Sandra
A1 Diehl-Schmid, Janine
A1 Farlow, Martin R.
A1 Edbauer, Dieter
A1 Woodruff, Bryan K.
A1 Caselli, Richard J.
A1 Donker Kaat, Laura L.
A1 Huey, Edward D.
A1 Reiman, Eric M.
A1 Mead, Simon
A1 King, Andrew
A1 Roeber, Sigrun
A1 Nana, Alissa L.
A1 Ertekin-Taner, Nilufer
A1 Knopman, David S.
A1 Petersen, Ronald C.
A1 Petrucelli, Leonard
A1 Uitti, Ryan J.
A1 Wszolek, Zbigniew K.
A1 Ramos, Eliana Marisa
A1 Grinberg, Lea T.
A1 Gorno Tempini, Maria Luisa
A1 Rosen, Howard J.
A1 Spina, Salvatore
A1 Piguet, Olivier
A1 Grossman, Murray
A1 Trojanowski, John Q.
A1 Keene, Dirk C.
A1 Lee-Way, Jin
A1 Prudlo, Johannes
A1 Geschwind, Daniel H.
A1 Rissman, Robert A.
A1 Cruchaga, Carlos
A1 Ghetti, Bernardino
A1 Halliday, Glenda M.
A1 Beach, Thomas G.
A1 Serrano, Geidy E.
A1 Arzberger, Thomas
A1 Herms, Jochen
A1 Boxer, Adam L.
A1 Honig, Lawrence S.
A1 Vonsattel, Jean P.
A1 Lopez, Oscar L.
A1 Kofler, Julia
A1 White, Charles L.
A1 Gearing, Marla
A1 Glass, Jonathan
A1 Rohrer, Jonathan D.
A1 Irwin, David J.
A1 Lee, Edward B.
A1 Van Deerlin, Vivianna
A1 Castellani, Rudolph
A1 Mesulam, Marsel M.
A1 Tartaglia, Maria C.
A1 Finger, Elizabeth C.
A1 Troakes, Claire
A1 Al-Sarraj, Safa
A1 Miller, Bruce L.
A1 Seelaar, Harro
A1 Graff-Radford, Neill R.
A1 Boeve, Bradley F.
A1 Mackenzie, Ian RA.
A1 van Swieten, John C.
A1 Seeley, William W.
A1 Sleegers, Kristel
A1 Dickson, Dennis W.
A1 Biernacka, Joanna M.
A1 Rademakers, Rosa
YR 2024
UL http://medrxiv.org/content/early/2024/06/25/2024.06.24.24309088.abstract
AB Frontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 43 (FTLD-TDP) is a fatal neurodegenerative disorder with only a limited number of risk loci identified. We report our comprehensive genome-wide association study as part of the International FTLD-TDP Whole-Genome Sequencing Consortium, including 985 cases and 3,153 controls, and meta-analysis with the Dementia-seq cohort, compiled from 26 institutions/brain banks in the United States, Europe and Australia. We confirm UNC13A as the strongest overall FTLD-TDP risk factor and identify TNIP1 as a novel FTLD-TDP risk factor. In subgroup analyses, we further identify for the first time genome-wide significant loci specific to each of the three main FTLD-TDP pathological subtypes (A, B and C), as well as enrichment of risk loci in distinct tissues, brain regions, and neuronal subtypes, suggesting distinct disease aetiologies in each of the subtypes. Rare variant analysis confirmed TBK1 and identified VIPR1, RBPJL, and L3MBTL1 as novel subtype specific FTLD-TDP risk genes, further highlighting the role of innate and adaptive immunity and notch signalling pathway in FTLD-TDP, with potential diagnostic and novel therapeutic implications.Competing Interest StatementRR and IRM receive royalties from progranulin-related patent.Funding StatementThis work was made possible by the support of funding from the UG3/UH3 NS103870, P30 AG062677, P01 AG003949, R01 AG037491, P01 NS084974, R01 AG37491, R01 DC12519, R21 NS94684, R01 DC010367, P30 AG062422, P01 AG019724, U01 AG057195, U19 AG063911, P30 AG077444, P30 AG013854, P30 AG07297, P30 AG066468, P30 AG012300, P30 AG072972, P30 AG010129, P50 AG005136, P30 AG066509, P30 AG066511, P01 AG066597, P30 AG072979, R01 AG077444, and R01 DC008552. Supported by the ALLFTD Consortium (U19: AG063911, funded by the NIA and NINDS) and the former ARTFL & LEFFTDS Consortia (ARTFL: U54 NS092089, funded by the NINDS and NCATS; LEFFTDS: U01 AG045390, funded by the NIA and NINDS). Supported by the Mayo ADRC (P30 AG62677, funded by the NIA). A subset of samples were obtained through the National Centralized Repository for Alzheimer Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG021886) awarded by the National Institute on Aging (NIA), were used in this study. The work was supported by Mayo Clinic Center for Regenerative Medicine, the gifts from the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, The Albertson Parkinson's Research Foundation, and PPND Family Foundation. This work was supported by TARGET ALS, the Rainwater Charitable Foundation and the Bluefield Project to Cure FTD, the DEC Brain and BioBank, CIHR grant 74580, the Canadian Consortium on Neurodegeneration in Aging, of the Canadian Institutes of Health Research, the University of Pittsburgh Brain Institute. This work was supported by the NIHR UCL/H Biomedical Research Centre, the UK MRC (MR/M008525/1; MR/M023664/1), the Bluefield Project and the JPND (2019-02248). This work was made possible, in part, by the Winspear Family Center for Research on the Neuropathology of Alzheimer disease, the McCune Foundation, and the Nancy and Buster Alvord endowment. Research was supported by Grants provided by Swedish FTD Initiative-Schorling foundation, the Swedish research Council (Dnr 521-2010-3134, 529-2014-7504, 2015-02926), Alzheimer Foundation Sweden, Brain Foundation Sweden, Swedish Brain Power, Gamla Tjanarinnor, Stohnes Foundation, Dementia Foundation Sweden and the Stockholm County Council (ALF-project). The brain pathology was provided through in part by the Brain Bank at Karolinska Institutet which was financially supported by Karolinska Institutet StratNeuro, Swedish Brain Power, Stockholm County Council core facility funding (CG) and Schorling Foundation. This work was supported in part by SAO-FRA 2021/0032. FK receives a postdoctoral fellowship (BOF 49758) from the University of Antwerp Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Mayo Clinic gave ethical approval of this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSummary statistics will be available on dbGAP platform post publication. Datasets and molecular QTLs used in the gene prioritization are publicly available (see also Supplementary Table 4): eQTLs and eTWAS reference panels in AD-relevant bulk brain regions from AMP-AD cohorts and in LCLs from the EADB Belgian cohort, as analyzed by Bellenguez et al.14: https://doi.org/10.5281/zenodo.5745927; sQTLs and sTWAS reference panels in AD-relevant bulk brain regions from AMP-AD cohorts and in LCLs from the EADB Belgian cohort, as analyzed by Bellenguez et al14.: https://doi.org/10.5281/zenodo.5745929; Bryois et al.83 ct-eQTL catalogues (https://doi.org/10.5281/zenodo.5543734); eQTL Catalogue database (https://www.ebi.ac.uk/eqtl/); Brain xQTL serve mQTL and haQTL catalogues (https://mostafavilab.stat.ubc.ca/xqtl/xQTL_updated_data/); GTEx v8 eQTL and sQTL catalogues (https://www.gtexportal.org/); GTEx v8 expression and splicing prediction models for eTWAS/sTWAS (https://predictdb.org/post/2021/07/21/gtex-v8-models-on-eqtl-and-sqtl/#mashr-based-models); MiGA eQTLs (https://doi.org/10.5281/zenodo.4118605); MiGA sQTLs (https://doi.org/10.5281/zenodo.4118403); MiGA meta-analysis (https://doi.org/10.5281/zenodo.4118676); and Wingo et al.86 pQTLs v2 (https://www.synapse.org/#!Synapse:syn23627957).